Dan Goldberger is the new CEO of Bacterin International Holdings, Inc.
Goldberger Replaces Cook at Bacterin
2 min read Premium comments
The announcement on August 7, 2013 stated that Goldberger is a named inventor on more than 60 U.S. patents and holds a BS in Mechanical Engineering from the Massachusetts Institute of Technology and an MS in Mechanical Engineering from Stanford University.
Most recently, Goldberger was CEO of Sound Surgical Technologies from April 2007 through the company’s merger with Solta Medical, Inc. in February 2013. With more than 25 years of experience in medical technology and the device industry, Goldberger has held several executive leadership positions within the medical device industry, as the CEO and director and Xcorporeal Inc. and president of Medical Group of OSI Systems, Inc.
C-Level Commercializer
Goldberger describes himself on his LinkedIn page as “A C-level commercializer and multifunctional operational executive, I specialize in driving revenue and growth in life sciences and healthcare companies. Recognized as a culture shaper and performance turnaround expert, I specialize in magnifying shareholder ROI and top-/bottom-line value gains.”
“Bacterin International is a formidable competitor in this burgeoning biologics and regenerative medicine space with an immense array of products and manufacturing capabilities. I am impressed with the foundation of business for which I have been given the responsibility to lead. I look forward to working with the company’s employees and customers, and driving the business into sustained profitability for its customers, employees and shareholders, ” said Goldberger in the company press release.
Bacterin Second Quarter
The company just reported second quarter sales of $8.3 million, up from the previous year’s $8.2 million. A net loss for the quarter totaled approximately $2.5 million. The company also closed on equity financing in June which netted the company $4.5 million. “Despite the challenges we incurred during the second quarter of 2013 associated with the resignation of our prior CEO, this was a satisfying quarter, ” said John Gandolfo, co-interim CEO and CFO on August 6, 2013.
Replacing Cook
Guy Cook, the company’s founder and previous CEO announced his intention in April to resign as president and CEO once a successor is selected.
Bacterin was founded in 1998 as a sole proprietorship by Cook as a spinout of the Center for Biofilm Engineering at Montana State University (CBE). Today, the company has over 150 employees and sales in over 15 countries.
“When starting this company over 15 years ago, we focused on utilizing the best technology for improving our products. It is extremely rewarding to see Bacterin evolve into a leader in regenerative biologics. We have created an expanding, diversified product portfolio that has positioned the company for continued growth, ” said Cook.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.